- Home
- JPI vs FHTX Comparison
JPI vs FHTX Comparison
Compare JPI & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JPI
- FHTX
- Stock Information
- Founded
- JPI 2012
- FHTX 2015
- Country
- JPI United States
- FHTX United States
- Employees
- JPI N/A
- FHTX N/A
- Industry
- JPI Finance Companies
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- JPI Finance
- FHTX Health Care
- Exchange
- JPI Nasdaq
- FHTX Nasdaq
- Market Cap
- JPI 440.4M
- FHTX 517.9M
- IPO Year
- JPI N/A
- FHTX 2020
- Fundamental
- Price
- JPI $20.91
- FHTX $7.74
- Analyst Decision
- JPI
- FHTX Strong Buy
- Analyst Count
- JPI 0
- FHTX 5
- Target Price
- JPI N/A
- FHTX $16.00
- AVG Volume (30 Days)
- JPI 54.7K
- FHTX 184.1K
- Earning Date
- JPI 01-01-0001
- FHTX 10-31-2024
- Dividend Yield
- JPI 6.15%
- FHTX N/A
- EPS Growth
- JPI N/A
- FHTX N/A
- EPS
- JPI N/A
- FHTX N/A
- Revenue
- JPI N/A
- FHTX $35,185,000.00
- Revenue This Year
- JPI N/A
- FHTX N/A
- Revenue Next Year
- JPI N/A
- FHTX $15.40
- P/E Ratio
- JPI N/A
- FHTX N/A
- Revenue Growth
- JPI N/A
- FHTX 61.95
- 52 Week Low
- JPI $16.02
- FHTX $2.70
- 52 Week High
- JPI $19.12
- FHTX $10.25
- Technical
- Relative Strength Index (RSI)
- JPI 59.46
- FHTX 46.15
- Support Level
- JPI $20.69
- FHTX $7.24
- Resistance Level
- JPI $21.10
- FHTX $8.35
- Average True Range (ATR)
- JPI 0.23
- FHTX 0.63
- MACD
- JPI -0.06
- FHTX -0.09
- Stochastic Oscillator
- JPI 43.41
- FHTX 27.49
About JPI Nuveen Preferred and Income Term Fund of Beneficial Interest
Nuveen Preferred and Income Term Fund is a closed-end management investment company. Its investment objective is to provide a high level of current income and total return. The company's products include mutual funds, closed-end funds, Exchange-traded funds, Multi-asset model portfolios, and others.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.